$16.97
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Apnimed, Inc. operates as a clinical-stage company. The company is headquartered in Cambridge, Massachusetts. The firm's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Key stats
Open
$17.68
Volume
466.54K
Market cap
$682.74M
Prev. close
$17.34
Impl / hst vl
-
Open interest
$0.00
$16.16
Day’s Range
$17.68
$16.12
52W Range
$35.29
Valuation
22
Valuation score
Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
97.45%
Income growth
-152.83%
FCF growth
-59.88
Analysts estimates
Consensus rating
Buy
The average rating from top 6 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$51.34
The top 5 analysts forecasts that 12-month price may increase by 202.53%, with a low of $41.41 and a high of $63.00
$41.41
Low
$51.34
Avg
$63.00
High
Current price
Earnings
Q1 ‘26 revenue
$84.81M
Q1 ‘26 net income
$67.72M
Revenue
Net income
Previous EPS
-Estimate EPS
-$0.52
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply